BioMark Diagnostics Inc.
BUX
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.39M | -1.45M | -1.20M | -1.06M | -1.14M |
| Total Depreciation and Amortization | 201.40K | 232.40K | 257.30K | 291.60K | 292.80K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 288.80K | 290.90K | 231.30K | 102.60K | 156.30K |
| Change in Net Operating Assets | 271.00K | 61.10K | -61.50K | -62.40K | -7.30K |
| Cash from Operations | -624.90K | -861.50K | -774.50K | -726.00K | -696.50K |
| Capital Expenditure | -2.70K | -4.30K | -5.00K | -3.20K | -2.30K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2.70K | -4.30K | -5.00K | -3.20K | -2.30K |
| Total Debt Issued | 378.20K | 357.20K | 357.20K | 357.20K | 357.20K |
| Total Debt Repaid | -773.70K | -1.07M | -1.20M | -1.18M | -989.70K |
| Issuance of Common Stock | 1.03M | 1.76M | 1.87M | 1.89M | 1.76M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 460.70K | 766.60K | 753.60K | 791.50K | 831.20K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -166.80K | -99.00K | -25.90K | 62.10K | 132.30K |